Home Imugene Limited

Imugene Limited

    Lens through Imugene’s September 2019 Quarterly 4C Report

    Biotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous...

    Imugene Commends City of Hope Researchers on Receiving US Department of Defense Grant

    As per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have received a Grant of USD 564,173 from the...

    Imugene Released Program Update on Oncolytic Virus CF33’s Phase 1 Clinical Trial Plans

    ASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on the preliminary clinical development plan for the intended exclusive license...

    Imugene Hires Professor Yuman Fong to Lead Oncolytic Virotherapy Scientific Advisory Board

    Australia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the development of various new and novel immunotherapies that attempt to stimulate...

    Imugene Reports Impressive B-cell vaccines Data at ESMO Congress 2019

    Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is engaged towards the development of several new and novel immunotherapies that work to activate...

    Imugene Progressing Rapidly With Its Strong Product Pipeline; Glimpse At Stock’s Technical Analysis

    Clinical stage immuno-oncology player headquartered in Australia, Imugene Limited (ASX: IMU) is engaged in the development of several new and unique immunotherapies that work...
    Immuno-Oncology Market Player, Imugene Delivers Remarkable Performance In FY 2019

    Immuno-Oncology Market Player, Imugene Delivers Remarkable Performance In FY 2019

    Clinical stage immuno-oncology firm headquartered in Australia, Imugene Limited (ASX: IMU) is engaged in the development of a wide range of new treatments that...
    Everything you Need to Know about Investing in Health Stocks; 3 related players to Watch- NEU, PXS, CPH

    A Deep Dive into Imugene’s Opportunities in the Immuno-oncology Market

    Imugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development of immunotherapies that have the potential to enable a...

    Imugene Goes Great Guns with Strong Management Team

    Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The...

    A Glance at Imugene’s B-Cell Vaccine Developments in 2019

    An Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks to develop different novel immunotherapies to boost the efficacy of cancer treatments. Imugene’s...

    Recent News